Verastem, Inc. (0LOV.L)
USD 4.46
(-7.56%)
USD 4.46
(-7.56%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -83.16 Million USD | -28.39% |
| 2022 | -71.55 Million USD | -17.06% |
| 2021 | -61.02 Million USD | -28.66% |
| 2020 | -50.41 Million USD | 62.36% |
| 2019 | -126.6 Million USD | -39.29% |
| 2018 | -65.2 Million USD | -36.1% |
| 2017 | -66.68 Million USD | -83.55% |
| 2016 | -35.77 Million USD | 37.57% |
| 2015 | -57.11 Million USD | -9.44% |
| 2014 | -52.93 Million USD | -29.18% |
| 2013 | -40.96 Million USD | -28.55% |
| 2012 | -31.77 Million USD | -135.2% |
| 2011 | -13.61 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -28.05 Million USD | -24.71% |
| 2024 Q2 | -18.27 Million USD | 78.27% |
| 2023 FY | - USD | -28.39% |
| 2023 Q3 | -18.87 Million USD | 18.5% |
| 2023 Q4 | -31.13 Million USD | -64.95% |
| 2023 Q2 | -23.16 Million USD | -54.97% |
| 2023 Q1 | -14.94 Million USD | 7.08% |
| 2022 Q1 | -16.9 Million USD | -2.64% |
| 2022 FY | - USD | -17.06% |
| 2022 Q4 | -16.08 Million USD | 7.42% |
| 2022 Q3 | -17.37 Million USD | 18.48% |
| 2022 Q2 | -21.31 Million USD | -26.06% |
| 2021 Q4 | -16.47 Million USD | -11.25% |
| 2021 Q3 | -14.8 Million USD | 6.65% |
| 2021 Q2 | -15.86 Million USD | -13.23% |
| 2021 Q1 | -14 Million USD | 23.32% |
| 2021 FY | - USD | -28.66% |
| 2020 Q3 | 15.27 Million USD | 173.87% |
| 2020 FY | - USD | 62.36% |
| 2020 Q1 | -26.81 Million USD | 18.28% |
| 2020 Q2 | -20.67 Million USD | 22.88% |
| 2020 Q4 | -18.26 Million USD | -219.58% |
| 2019 FY | - USD | -39.29% |
| 2019 Q4 | -32.8 Million USD | -33.61% |
| 2019 Q3 | -24.55 Million USD | 32.63% |
| 2019 Q2 | -36.44 Million USD | -11.76% |
| 2019 Q1 | -32.61 Million USD | -372.55% |
| 2018 Q3 | -20.67 Million USD | -20.32% |
| 2018 Q4 | -6.9 Million USD | 66.62% |
| 2018 Q2 | -17.18 Million USD | 15.95% |
| 2018 Q1 | -20.44 Million USD | -15.0% |
| 2018 FY | - USD | -36.1% |
| 2017 FY | - USD | -83.55% |
| 2017 Q1 | -12.84 Million USD | -10.29% |
| 2017 Q4 | -17.77 Million USD | 22.29% |
| 2017 Q3 | -22.87 Million USD | -73.54% |
| 2017 Q2 | -13.18 Million USD | -2.62% |
| 2016 Q2 | -8.53 Million USD | -3.42% |
| 2016 Q3 | -7.9 Million USD | 7.42% |
| 2016 Q1 | -8.25 Million USD | 29.92% |
| 2016 FY | - USD | 37.57% |
| 2016 Q4 | -11.64 Million USD | -47.44% |
| 2015 FY | - USD | -9.44% |
| 2015 Q4 | -11.77 Million USD | 23.28% |
| 2015 Q3 | -15.34 Million USD | -0.47% |
| 2015 Q2 | -15.27 Million USD | -1.45% |
| 2015 Q1 | -15.05 Million USD | -8.98% |
| 2014 FY | - USD | -29.18% |
| 2014 Q3 | -13.28 Million USD | -2.13% |
| 2014 Q2 | -13.01 Million USD | 0.46% |
| 2014 Q1 | -13.07 Million USD | -15.35% |
| 2014 Q4 | -13.81 Million USD | -3.96% |
| 2013 FY | - USD | -28.55% |
| 2013 Q1 | -9.02 Million USD | -14.02% |
| 2013 Q2 | -10.22 Million USD | -13.33% |
| 2013 Q3 | -10.58 Million USD | -3.46% |
| 2013 Q4 | -11.33 Million USD | -7.08% |
| 2012 Q2 | -6.84 Million USD | 0.49% |
| 2012 FY | - USD | -135.2% |
| 2012 Q1 | -6.88 Million USD | -15.08% |
| 2012 Q3 | -10.37 Million USD | -51.55% |
| 2012 Q4 | -7.91 Million USD | 23.73% |
| 2011 Q4 | -5.98 Million USD | -48.94% |
| 2011 Q3 | -4.01 Million USD | -61.57% |
| 2011 Q2 | -2.48 Million USD | -116.84% |
| 2011 Q1 | -1.14 Million USD | 0.0% |
| 2011 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Thermo Fisher Scientific Inc. | 10.8 Billion USD | 100.77% |
| Dynavax Technologies Corporation | 9.66 Million USD | 960.397% |
| Illumina, Inc. | -608 Million USD | 86.321% |
| IQVIA Holdings Inc. | 3.25 Billion USD | 102.554% |
| Biogen Inc. | 2.37 Billion USD | 103.499% |
| Iovance Biotherapeutics, Inc. | -449.01 Million USD | 81.478% |
| Mettler-Toledo International Inc. | 1.16 Billion USD | 107.145% |
| Sarepta Therapeutics, Inc. | -439.19 Million USD | 81.064% |
| Supernus Pharmaceuticals, Inc. | 98.26 Million USD | 184.637% |
| Waters Corporation | 1.02 Billion USD | 108.136% |
| Perrigo Company plc | 646.2 Million USD | 112.87% |
| uniQure N.V. | -253.1 Million USD | 67.141% |
| Agios Pharmaceuticals, Inc. | -345.46 Million USD | 75.926% |
| Amicus Therapeutics, Inc. | -92.07 Million USD | 9.68% |
| Atara Biotherapeutics, Inc. | -265.99 Million USD | 68.734% |
| bluebird bio, Inc. | -167.16 Million USD | 50.248% |
| Cara Therapeutics, Inc. | -117.65 Million USD | 29.311% |
| Imunon, Inc. | -20.78 Million USD | -300.178% |
| Myriad Genetics, Inc. | -67.8 Million USD | -22.664% |
| Neurocrine Biosciences, Inc. | 416.1 Million USD | 119.987% |
| Nektar Therapeutics | -243.1 Million USD | 65.79% |
| Editas Medicine, Inc. | -163.11 Million USD | 49.015% |
| Walgreens Boots Alliance, Inc. | -11.27 Billion USD | 99.263% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.43 Million USD | -87.156% |
| Heron Therapeutics, Inc. | -103.79 Million USD | 19.872% |
| Unity Biotechnology, Inc. | -37.28 Million USD | -123.067% |
| BioMarin Pharmaceutical Inc. | 310.28 Million USD | 126.803% |
| Sangamo Therapeutics, Inc. | -87.42 Million USD | 4.874% |
| Evolus, Inc. | -41.81 Million USD | -98.914% |
| Adicet Bio, Inc. | -136.53 Million USD | 39.088% |
| Aclaris Therapeutics, Inc. | -87.98 Million USD | 5.477% |
| Regeneron Pharmaceuticals, Inc. | 4.65 Billion USD | 101.787% |
| Esperion Therapeutics, Inc. | -150.1 Million USD | 44.596% |
| FibroGen, Inc. | -261.4 Million USD | 68.185% |
| Agilent Technologies, Inc. | 1.67 Billion USD | 104.959% |
| OPKO Health, Inc. | -65.51 Million USD | -26.94% |
| Homology Medicines, Inc. | -47.75 Million USD | -74.148% |
| Geron Corporation | -174.78 Million USD | 52.417% |
| Alnylam Pharmaceuticals, Inc. | -228.12 Million USD | 63.543% |
| Exelixis, Inc. | 196.6 Million USD | 142.302% |
| Viking Therapeutics, Inc. | -100.82 Million USD | 17.516% |
| Anavex Life Sciences Corp. | -55.75 Million USD | -49.161% |
| Intellia Therapeutics, Inc. | -506.31 Million USD | 83.574% |
| Zoetis Inc. | 3.68 Billion USD | 102.257% |
| Axsome Therapeutics, Inc. | -224.99 Million USD | 63.036% |
| Abeona Therapeutics Inc. | -50.57 Million USD | -64.451% |
| Vertex Pharmaceuticals Incorporated | 4.6 Billion USD | 101.806% |
| Kala Pharmaceuticals, Inc. | -36.08 Million USD | -130.492% |
| Ionis Pharmaceuticals, Inc. | -230.01 Million USD | 63.842% |
| Corcept Therapeutics Incorporated | 108.32 Million USD | 176.775% |
| Halozyme Therapeutics, Inc. | 451.94 Million USD | 118.402% |
| Blueprint Medicines Corporation | -474.61 Million USD | 82.477% |
| Insmed Incorporated | -654.73 Million USD | 87.298% |
| TG Therapeutics, Inc. | 26.1 Million USD | 418.644% |
| Incyte Corporation | 919.42 Million USD | 109.045% |
| Emergent BioSolutions Inc. | -505.29 Million USD | 83.541% |